The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease
Open accessAbstract
The endothelium is the orchestral conductor of blood vessel function. Pathological blood vessel formation (a process termed pathological angiogenesis) or the inability of endothelial cells ( EC s) to perform their physiological function (a condition known as EC dysfunction) are defining features of various diseases. Therapeutic intervention to inhibit aberrant angiogenesis or ameliorate EC dysfunction could be beneficial in diseases such as cancer and cardiovascular disease, respectively, but current strategies have limited efficacy. Based on recent findings that pathological angiogenesis and EC dysfunction are accompanied by EC ‐specific metabolic alterations, targeting EC metabolism is emerging as a novel therapeutic strategy. Here, we review recent progress in our understanding of how EC metabolism is altered in disease and discuss potential metabolic targets and strategies to reverse EC dysfunction and inhibit pathological angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationOxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 2×
“…endothelial growth factor (VEGF) signaling) is the only clinically approved anti-angiogenic strategy, but the benefits are limited as tumors acquire resistance within months after treatment initiation (Bergers & Hanahan, 2008; Carme-liet & Jain, 2011; Ebos & Kerbel, 2011; Welti et al , 2013).”
Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres
Lin, J., Wu, H., Tarr, P. T., Zhang, C.-Y., Wu, Z., Boss, O., Michael, L. F., Puigserver, P., Isotani, E., Olson, E. N., et al. (2002) · Nature · doi:10.1038/nature00904 · Cited by 2,546 · cited 1×
“Hyperglycemia induces peroxisome proliferator-activated receptor-gamma coactivator 1a (PGC-1a), an important regulator of metabolic gene expression and mitochondrial biogenesis (Puigserver et al, 1998; Herzig et al, 2001; Lin et al, 2002).”
BackgroundRole of Endothelial Dysfunction in Atherosclerosis
Davignon, J., & Ganz, P. (2004) · Circulation · doi:10.1161/01.cir.0000131515.03336.f8 · Cited by 2,513
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 1×
“…with recent findings that glycolysis regulates angiogenesis, hyperproliferative PAH ECs rely on increased glycolytic flux and reduced oxygen consumption, which may be related to HIF-1 a overexpression (Fig 2B) (Xu et al , 2007; Fijalkowska et al , 2010; Majmundar et al , 2010; Tuder et al , 2012).”
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261
IAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756
HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α
Arany, Z., Foo, S.-Y., Ma, Y., Ruas, J. L., Bommi-Reddy, A., Girnun, G., Cooper, M., Laznik, D., Chinsomboon, J., Rangwala, S. M., et al. (2008) · Nature · doi:10.1038/nature06613 · Cited by 1,054 · cited 1×
“PGC1 a increases angiogenesis when expressed in heart and muscle cells (Arany et al , 2008; Patten et al , 2012).”
Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase
Laufs, U., & Liao, J. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24266 · Cited by 1,035 · cited 1×
“For proper activation and localization to the cell membrane, RhoA must be prenylated (more specifically, geranylgeranylated) by geranylgeranyltransferase (GGT) using geranylgeranyl pyrophosphate (GGPP) as a substrate (Laufs & Liao, 1998).”
MethodDu, X. L., Edelstein, D., Dimmeler, S., Ju, Q., Sui, C., & Brownlee, M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11235 · Cited by 907 · cited 1×
“While glycosylation is important for physiological EC function, hyperglycemia-induced protein glycosylation inhibits angiogenic functions (Du et al , 2001; Federici et al , 2002; Luo et al , 2008).”
Végran, F., Boidot, R., Michiels, C., Sonveaux, P., & Feron, O. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2828 · Cited by 816 · cited 1×
“Stabilized HIF-1 a induces pro-angiogenic signaling pathways such as nuclear factor kappa-light-chain-enhancer of activated B-cells (NFkB)/interleukin 8 (IL-8) leading to increased angiogenesis (Fig 2A) (Hunt et al , 2007; Vegran et al , 2011; Sonveaux et al , 2012).”
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809 · cited 2×
“Cancer Tumors need blood vessels to supply oxygen and detoxify waste products (Jain, 1987; Papetti & Herman, 2002; Welti et al , 2013).”
Compartmentalization of Mammalian Folate-Mediated One-Carbon Metabolism
Tibbetts, A. S., & Appling, D. R. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104810 · Cited by 692 · cited 1×
“One-carbon (1C) metabolism centers around the ability of folate-derived co-enzymes to carry activated 1C units (Fig 3) (Tibbetts & Appling, 2010).”
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685 · cited 1×
“…endothelial growth factor (VEGF) signaling) is the only clinically approved anti-angiogenic strategy, but the benefits are limited as tumors acquire resistance within months after treatment initiation (Bergers & Hanahan, 2008; Carme-liet & Jain, 2011; Ebos & Kerbel, 2011; Welti et al , 2013).”
Sonveaux, P., Copetti, T., De Saedeleer, C. J., Végran, F., Verrax, J., Kennedy, K. M., Moon, E. J., Dhup, S., Danhier, P., Frérart, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033418 · Cited by 536
Homocysteine lowering interventions for preventing cardiovascular events
Martí-Carvajal, A. J., Solà, I., Lathyris, D., & Salanti, G. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006612.pub2 · Cited by 520
Inoguchi, T., Sonta, T., Tsubouchi, H., Etoh, T., Kakimoto, M., Sonoda, N., Sato, N., Sekiguchi, N., Kobayashi, K., Sumimoto, H., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077407.90309.65 · Cited by 435
Heitzer, T., Krohn, K., Albers, S., & Meinertz, T. (2000) · Diabetologia · doi:10.1007/s001250051551 · Cited by 427
Xu, W., Kaneko, F. T., Zheng, S., Comhair, S. A. A., Janocha, A. J., Goggans, T., Thunnissen, F. B. J. M., Farver, C., Hazen, S. L., Jennings, C., et al. (2004) · The FASEB Journal · doi:10.1096/fj.04-2317fje · Cited by 369
Böger, R. H. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.10.2842s · Cited by 363
Endothelial Arginase II: A Novel Target for the Treatment of Atherosclerosis
Ryoo, S., Gupta, G., Benjo, A., Lim, H. K., Camara, A., Sikka, G., Lim, H. K., Sohi, J., Santhanam, L., Soucy, K., et al. (2008) · Circulation Research · doi:10.1161/circresaha.107.169573 · Cited by 236 · cited 2×
“Endothelial arginase expression is induced by many risk factors for cardiovascular disease, while reducing arginase expression restores NO production in vitro and improves vasodilatation in vivo (Ryoo et al , 2006, 2008; Thengchaisri et al , 2006; Romero et al , 2008).”
Tetrahydrobiopterin in Cardiovascular Health and Disease
Bendall, J. K., Douglas, G., McNeill, E., Channon, K. M., & Crabtree, M. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5566 · Cited by 231 · cited 2×
“Importantly, inactivating mutations in the MTHFR gene result in hyperhomocysteinemia, which decreases GTPCH and DHFR levels and may subsequently reduce BH4 levels (Bendall et al , 2014).”
Crabtree, M. J., Tatham, A. L., Hale, A. B., Alp, N. J., & Channon, K. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.041483 · Cited by 210
Unlocking the biology of RAGE in diabetic microvascular complications
Manigrasso, M. B., Juranek, J., Ramasamy, R., & Schmidt, A. M. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.08.002 · Cited by 209
Crabtree, M. J., Tatham, A. L., Al-Wakeel, Y., Warrick, N., Hale, A. B., Cai, S., Channon, K. M., & Alp, N. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805403200 · Cited by 200 · cited 2×
“…important enzymes in GTP and folate metabolism, respectively, have been associated with reduced BH4 availability, endothelial dysfunction and cardiovascular disease in several preclinical models (Chalupsky & Cai, 2005; Crabtree et al , 2009b, 2011; Sugiyama et al , 2009; Kidokoro et al , 2013).”
Control of angiogenesis by AIBP-mediated cholesterol efflux
Fang, L., Choi, S.-H., Baek, J. S., Liu, C., Almazan, F., Ulrich, F., Wiesner, P., Taleb, A., Deer, E., Pattison, J., et al. (2013) · Nature · doi:10.1038/nature12166 · Cited by 192
Cunnington, C., Van Assche, T., Shirodaria, C., Kylintireas, I., Lindsay, A. C., Lee, J. M., Antoniades, C., Margaritis, M., Lee, R., Cerrato, R., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.038919 · Cited by 166
Cited by
Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis
Gimbrone, M. A., & García-Cardeña, G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306301 · Cited by 3,476
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Metabolic Instruction of Immunity
Buck, M. D., Sowell, R. T., Kaech, S. M., & Pearce, E. L. (2017) · Cell · doi:10.1016/j.cell.2017.04.004 · Cited by 1,214
Yang, E., Wang, X., Gong, Z., Yu, M., Wu, H., & Zhang, D. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00359-5 · Cited by 494
Yang, L., Achreja, A., Yeung, T.-L., Mangala, L. S., Jiang, D., Han, C., Baddour, J., Marini, J. C., Ni, J., Nakahara, R., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.011 · Cited by 429
Metadata
- Authors
- Goveia, J., Stapor, P., & Carmeliet, P.
- Venue
- EMBO Molecular Medicine
- Published
- 2014-07-25
- Volume
- 6
- Issue
- 9
- Pages
- 1105-1120
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2096823131
- Cited by
- 200
- References
- 32
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.